TY  - GEN
AU  - D'Arena,Giovanni
AU  - Simeon,Vittorio
AU  - Laurenti,Luca
AU  - Cimminiello,Michele
AU  - Innocenti,Idanna
AU  - Gilio,Michele
AU  - Padula,Angela
AU  - Vigliotti,Maria Luigia
AU  - De Lorenzo,Sonya
AU  - Loseto,Giacomo
AU  - Passarelli,Anna
AU  - Di Minno,Matteo Nicola Dario
AU  - Tucci,Marco
AU  - De Feo,Vincenzo
AU  - D'Auria,Fiorella
AU  - Silvestris,Francesco
AU  - Di Minno,Giovanni
AU  - Musto,Pellegrino
TI  - Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients
SN  - 1029-2403
PY  - 2018///0417
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Autoimmune Diseases
KW  - drug therapy
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - blood
KW  - Female
KW  - Hematologic Neoplasms
KW  - Humans
KW  - Infusions, Intravenous
KW  - Male
KW  - Middle Aged
KW  - Prognosis
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Rituximab
KW  - Young Adult
N1  - Publication Type: Journal Article; Multicenter Study; Observational Study
UR  - https://doi.org/10.1080/10428194.2017.1306648
ER  -